Piperazine Derivatives Research Articles

2,3-Dichloronaphthoquinone derivatives: Synthesis, antimicrobial activity, molecular modelling and ADMET studies

In the present study, an intermediate namely 2-(3-bromopropylamino)-3-chloronaphthalene-1,4-dione was initially synthesized via the nucleophilic addition–elimination reaction between 2,3-dichloro-1,4-naphthoquinone and 3-bromo-1-aminopropane. Then a coupling reaction between the intermediate and piperazine derivatives yielded a number of 1,4-naphthoquinone derivatives. Spectroscopic analysis successfully characterized the products that were obtained in good yields. In vitro antibacterial properties of the compounds were examined against different bacterial strains. In vitro antibacterial properties of the compounds were examined against the bacterial strains S. Aureus, E. Faecalis, E. Coli and P. Aeruginosa. While compound 9 was found to be effective against all bacterial strains used, compound 12 was active against three strains and compounds 10 and 11 were effective against the two. None of the compounds are effective against C. albicans strain. In silico molecular docking studies revealed that all compounds had docking scores comparable to the antibacterial drugs ciprofloxacin and gentamicin and might be considered as DNA gyrase B inhibitors. Molecular dynamics simulations were also conducted for a better understanding of the stability and the selected docked complexes. Additionally, the drug similarity of the synthesized compounds and ADMET characteristics were examined in conjunction with the antibiotic ciprofloxacin, and drug potentials were then evaluated. Compatible predictions were found with the drug similarity and ADMET parameters.

Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis

Liver fibrosis is commonly occurred in chronic liver diseases, but there is no approved drug for clinical use. The nuclear receptor peroxisome proliferator-activated receptors (PPARs) could not only regulate metabolic homeostasis but also possess anti-inflammatory and antifibrotic effects, and pan-PPARs agonist was considered as a potential anti-liver fibrosis agent. In this study, a series of novel piperazine pan-PPARs agonists were developed, and the preferred compound 12 displayed potent and well-balanced pan-PPARs agonistic activity. Moreover, compound 12 could dose-dependently stimulate the PPARs target genes expression and showed high selectivity over other related nuclear receptors. Importantly, compound 12 exhibited excellent pharmacokinetic profiles and good anti-liver fibrosis effects in vivo. Collectively, compound 12 holds promise for developing an anti-liver fibrosis agent.

Cryptic piperazine derivatives activated by knocking out the global regulator LaeA in Aspergillus flavipes

Genome sequencing on an intertidal zone-derived Aspergillus flavipes strain revealed its great potential to produce secondary metabolites. To activate the cryptic compounds of A. flavipes, the global regulator flLaeA was knocked out, leading to substantial up-regulation of the expression of two NRPS-like biosynthetic gene clusters in the ΔflLaeA mutant. With a scaled-up fermentation of the ΔflLaeA strain, five compounds, including two previously undescribed piperazine derivatives flavipamides A and B (1 and 2), along with three known compounds (3–5), were obtained by LC-MS guided isolation. The new compounds were elucidated by spectroscopic analysis and electronic circular dichroism (ECD) calculations, and the biosynthetic pathway was proposed on the bias of bioinformatic analysis and 13C isotope labeling evidence. This is the first report to access cryptic fungi secondary metabolites by inactivating global regulator LaeA and may provide a new approach to discovering new secondary metabolites by such genetic manipulation.

N-Aryl-DABCO Salts as an Unprecedented Sensing Platform for the Detection of Thiols and Selenols.

Quaternary N-aryl-DABCO salts were introduced for the first time as a highly selective sensing platform for thiols and selenols. By employing this platform, a highly sensitive coumarin based "off-on" fluorescent probe was designed and synthesized. The probe possesses a good solubility in water, low background fluorescence, and, most importantly, demonstrates high selectivity to aryl thiols and selenols over their aliphatic counterparts and other common nucleophiles. A dramatic increase in fluorescence intensity is achieved through the selective cleavage of the quaternized DABCO-ring, yielding a piperazine derivatives with a high fluorescence quantum yield (~72 %). Moreover, stability of the probe to the most used reducing agents DTT and TCEP was demonstrated. The limits of detection for p-thiocresol and phenyl selenide were evaluated to be 22 nM and 6 nM, respectively.

Photoinduced dehydrogenation of protected piperazines

Abstract Piperazine represents one of the most important building blocks of pharmaceuticals. Hence, the development of various piperazine derivatives is important. Herein we report photoinduced dehydrogenation of protected piperazines. The reaction proceeded with various alkyl-substituted piperazines. The resulting products have electron-rich olefin moieties that can react with benzyne, carbene, or acyl anhydride.

Fixed Drug Eruptions Due To/Caused by Levocetirizine and Cetirizine: An Uncommon Adverse Cutaneous Drug Reaction to Commonly Used Piperazine Derivatives.

Fixed Drug Eruptions Due To/Caused by Levocetirizine and Cetirizine: An Uncommon Adverse Cutaneous Drug Reaction to Commonly Used Piperazine Derivatives.

Tertiary Amines as Temporary Masked Secondary Amines: A Direct Access to 5-Dialkylamino-1,2,4-oxadiazoles from 1,2,4-Oxadiazol-5(4H)-ones

AbstractA novel strategy utilizing tertiary amines as temporary masked secondary amines to synthesize 5-dialkylamino 1,2,4-oxadiazoles via Ph3P-I2 mediated amination of 1,2,4-oxadiazol-5(4H)-ones was developed. A one-step N-dealkylative functionalization of tertiary amines with the 1,2,4-oxadiazole ring enables a convenient access to diverse 5-amino-1,2,4-oxadiazoles. Additionally, orthogonally functionalized piperazine derivatives can be effectively constructed through site-selective reaction of 1,4-dialkylpiperazines or via a sequential N-functionalization of 1-methylpiperazine obviating laborious protection/deprotection steps.

Neuropharmacological Potential of Different Piperazine Analogs: A Recent Prospective

Abstract: Heterocyclic moiety is a key part of some enzymes and vitamins and plays a vital role in various biochemical and enzymatic processes. Piperazine ring is a heterocyclic moiety present in various well-known drugs and is effective against different types of diseases by acting on a variety of receptors. Various piperazine analogs possess diverse biological activities, especially in central nervous system disorders, which involve the activation of neurotransmitter receptors and targeting various enzymes and act as antianxiety, antipsychotic, antidepressant, etc. This review is focused on the piperazine derivatives and their diverse therapeutic potential against different types of diseases particularly against neuronal disorders.

Docking, synthesis, and anticancer assessment of novel quinoline-amidrazone hybrids

A group of new amidrazone compounds that include a quinoline component was produced through the reaction of hydrazonyl chloride, derived from 6-aminoquinoline, with appropriate secondary cyclic amines. The new compounds were confirmed through 1H-NMR, 13C-NMR, FTIR, and HRMS, and further verified by single-crystal X-ray diffraction. The antitumor potential of the synthesized compounds was tested against lung cancer (A549) and breast cancer (MCF-7) cell lines. Among the compounds, the ethyl carboxylate and o-hydroxy phenyl piperazine derivatives (10d and 10g) exhibited the strongest activity against both cell lines, with IC50 values of 43.1 and 59.1 μM for the lung and breast cancer cell lines, respectively. Moreover, the most potent compounds were subsequently docked into the c-Abl kinase binding site (PDB code: 1IEP) as a possible anticancer mechanism. In-silico ADMET study shows acceptable pharmacokinetic properties, and the toxicity profile for the most potent compounds is non-carcinogenic.

Second-generation piperazine derivatives as promising radiation countermeasures.

The increasing threat of nuclear incidents and the widespread use of ionizing radiation (IR) in medical treatments underscore the urgent need for effective radiation countermeasures. Despite the availability of compounds such as amifostine, their clinical utility is significantly limited by adverse side effects and logistical challenges in administration. This study focuses on the synthesis and evaluation of novel piperazine derivatives as potential radioprotective agents, with the aim of overcoming the limitations associated with current countermeasures. We designed, synthesized, and evaluated a series of 1-(2-hydroxyethyl)piperazine derivatives. The compounds were assessed for cytotoxicity across a panel of human cell lines, and for their radioprotective effects in the MOLT-4 lymphoblastic leukemia cell line and in peripheral blood mononuclear cells (PBMCs) exposed to gamma radiation. The radioprotective efficacy was further quantified using the dicentric chromosome assay (DCA) to measure DNA damage mitigation. Among the synthesized derivatives, compound 6 demonstrated the most significant radioprotective effects in vitro, with minimal cytotoxicity across the tested cell lines. Compound 3 also showed notable efficacy, particularly in reducing dicentric chromosomes, thus indicating its potential to mitigate DNA damage from IR. Both compounds exhibited superior safety profiles and effectiveness compared to amifostine, suggesting their potential as more viable radioprotective agents. This study highlights the development of novel piperazine derivatives with promising radioprotective properties. Compound 6 emerged as the leading candidate, offering an optimal balance between efficacy and safety, with compound 3 also displaying significant potential. These findings support the further development and clinical evaluation of these compounds as safer, and more effective radiation countermeasures.

Design, synthesis, and evaluation of benzhydrylpiperazine-based novel dual COX-2/5-LOX inhibitors with anti-inflammatory and anti-cancer activity.

Piperazine derivatives were screened using the ChEMBL database, paving the way for the design, synthesis, and evaluation of a novel series of dual COX-2/5-LOX inhibitors and identifying their role in mitigating cancer cell proliferation. Compound 9d with 4-Cl substitution at the terminal phenyl ring showed promising inhibition of COX-2 (IC50 = 0.25 ± 0.03 μM) and 5-LOX (IC50 = 7.87 ± 0.33 μM), outperforming the standards celecoxib (IC50 = 0.36 ± 0.023 μM) and zileuton (IC50 = 14.29 ± 0.173 μM), respectively. The two most active derivatives 9d and 9g indicated a significant anti-inflammatory response in a paw edema model by inhibiting PGE2, IL-6, and TNF-α and an increase in IL-10 concentrations. Interestingly, 9d effectively reduced pain by 55.78%, closely comparable to the 59.09% exhibited by the standard indomethacin, and was also devoid of GI, liver, kidney, and cardiac toxicity. Furthermore, 9d demonstrated anti-cancer potential against in vitro A549, COLO-205, and MIA-PA-CA-2 human cancer cell lines and an in vivo Drosophila cancer model. The pharmacokinetic investigations revealed that 9d has good oral absorption characteristics.

Evaluation of anti-hemolytic and cytotoxic effects of novel piperazine derivatives

Evaluation of anti-hemolytic and cytotoxic effects of novel piperazine derivatives

Synthesis and Biological Evaluation of Cholic Acid Tagged Piperazine Derivatives

Abstract: Diseases caused by bacteria are a big challenge for scientists worldwide. These bacteria can be resistant through the adaption of new ways to protect themselves against antimicrobial drugs and thus become multidrug resistance. In this work, new derivatives of 1,3,4-oxadiazole- cholic acid were synthesized and fully characterized using different techniques, such as 1H-NMR, 13C-NMR, and HRMS. Their biological activity, along with the measuring of their minimal inhibitory concentration (MIC), was studied and reported. The antimicrobial activity of the new library was assessed via in vitro screening against both Gram-positive and Gram-negative bacteria. The compounds showed selectivity against Gram-positive bacteria. Among the new analogues, compounds 4F and 5h were found to be potent against S. aureus with MIC of 47 μg/mL. Compounds 4f, 5g and 5h were active against MRSE with MIC of 188, 99, and 23 μg/mL, respectively.

A Review on 1,2,3 - Triazole & Piperazine Derivatives with Various Biological Activities

The largest family of organic molecules in organic chemistry are heterocyclic compounds. A heterocyclic compound is created when an oxygen, nitrogen, sulphur, or atom of a similar element is included in place of a carbon atom. Heterocyclic compounds play a crucial role in daily living. It has a wide scope of uses in agrochemicals and medicinal chemistry. One of a pair of chemical compounds known as triazoles and Piperazine, with the molecular formula C2H3N3 and C5H5N. A fundamental aromatic heterocyclic scaffold is 1,2,3-triazole and piperazine. Because of its structural characteristics, these moiety’s are valuable in material science and due to its extensive application in chemistry, these can also be synthesized from readily available compounds. This literature review sheds light on the fact that 1,2,3-triazole and piperazine of hetero compounds are profoundly receptive and are known to possess potent diverse activities like, analgesic, anti-HIV, antimalarial, antiviral, anti-inflammatory, anticancer, antibacterial, antifungal, anthelmintic, and so forth. In conclusion numerous biological actions of the Piperazine and 1,2,3-Triazole derivatives of heterocyclic compounds were detailed and reviewed in this review. Keywords: 1,2,3 - Triazole; Biological activities; Piperazine; Anticancer Activity

A positive allosteric modulator of TRPC6 promotes neuroprotective effects <i> in vitro </i>

Alzheimer’s disease is a neurodegenerative disorder and the primary cause of dementia among elderly individuals. Unfortunately, there is no known cure for Alzheimer’s disease. Recently, a TRPC6-mediated intracellular signaling pathway was discovered, which plays a vital role in memory formation by regulating dendritic spine stability. Knockdown of TRPC6 expression was found to prevent store-operated calcium entry. The overexpression of TRPC6 or its pharmacological activation restores store-operated calcium entry in hippocampal neurons affected by Alzheimer’s disease [1, 2]. TRPC6 overexpression rescues mushroom spine loss in presenilin and APP knock-in mouse models of Alzheimer’s disease [1] and protects neurons from ischemic brain damage. Mice that overexpress TRPC6 in the brain exhibit improved cognitive function and increased excitatory synapse formation. These findings propose TRPC6 as a promising molecular target for the treatment of synaptic deficiency. We recently demonstrated that compound 51164 (N-(2-chlorophenyl)-2-(4-phenylpiperazine-1-yl) acetamide), a piperazine derivative, enhances TRPC6 channels and induces an upregulation of postsynaptic neuronal store-operated calcium entry. Furthermore, it increases mushroom spine percentage and recovers synaptic plasticity in mouse models of Alzheimer’s disease that have an amyloidogenic nature [2]. However, additional investigations of 51164 have demonstrated that the compound is unstable in plasma and cannot penetrate the blood-brain barrier (unpublished data). As such, the aim of this study is to discover a new piperazine derivative that functions as a positive modulator for TRPC6-specific and showcases neuroprotective qualities. In this study, we present in silico and in vitro investigations of a novel TRPC6 specific modulator. Based on our in silico research, we narrowed down the selection to 14 compounds through the piperazine derivative 51164 that met all drug-lead likeness criteria and showed a high affinity for the active center of TRPC6. Calcium imaging technique was usedto establish that the compound z12_30 triggered the activation of TRPC6 but not the structurally linked TRPC3 channel. In addition, a molecular dynamics approach revealed that z12_30 forms a stable complex with the TRPC6 active site. As a result, z12_30 was selected as the lead compound for further investigation. Studies showed that z12_30 safeguards hippocampal mushroom spines from amyloid toxicity in vitro and effectively restores synaptic plasticity in brain slices from aged 5xFAD mice. Preclinical trials demonstrate that z12_30 remains stable in both human and mouse plasma samples. We suggest that z12_30 is a promising prototype of a TRPC6-selective drug suitable for treating synaptic deficiency in hippocampal neurons affected by Alzheimer’s disease.

Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HT1AR/BDNF/PKA pathway

In this study, four series of piperazine derivatives were designed, synthesised and subjected to biological test, and compound 6a with potential antidepressant activity was obtained. An affinity assay of compound 6a with 5-hydroxytryptamine (serotonin, 5-HT)1A receptor (5-HT1AR) was undertaken, and the effects on the 5-HT level in the brains of mice were also tested. The results showed that compound 6a had the best affinity with 5-HT1AR (Ki = 1.28 nM) and significantly increased the 5-HT level. The expression levels of 5-HT1AR, BDNF, and PKA in the hippocampus were analysed by western blot and immunohistochemistry analyses. The results showed that the expression of 5-HT1AR, BDNF, and PKA in the model group was reduced compared to that of the control group, and compound 6a could reverse this phenomenon. Molecular docking was performed to investigate the interactions of the studied compound 6a with 5-HT1AR on the molecular level.

99mTc(CO)3-labeled 1-(2-Pyridyl)piperazine derivatives as radioligands for 5-HT7 receptors.

The 5-hydroxytryptamine receptor (5-HTR) family includes seven classes of receptors. The 5-HT7R is the newest member of this family and contributes to different physiological and pathological processes. As a pathology, glioblastoma multiform (GBM) overexpresses 5-HT7R; hence, this study aims to develop radiolabeled aryl piperazine derivatives as 5-HT7R imaging agents. METHODS: Compounds 6 and 7 as 1-(3-nitropyridin-2-yl)piperazine derivatives were radiolabeled with fac-[99mTc(CO)3(H2O)3]+ and 99mTc(CO)3-[6] and 99mTc(CO)3-[7] were obtained with high radiochemical purity (RCP > 94%).The stability of the radiotracers was evaluated in both saline and mouse serum. Specific binding on different cell lines including U-87 MG, MCF-7, SKBR3, and HT-29 was performed. The biodistribution of these radiotracers was evaluated in normal and U-87 MG Xenografted models. Finally, 99mTc(CO)3-[6] and 99mTc(CO)3-[7] were applied for in vivo imaging in U-87 MG Xenografted models. Specific binding study indicates that 99mTc(CO)3-[6] and 99mTc(CO)3-[7] can recognize 5-HT7R of U87-MG cell line. The biodistribution study in normal mice indicates that the brain uptake of 99mTc(CO)3-[6] and 99mTc(CO)3-[7] is the highest at 30min post-injection (0.8 ± 0.25 and 0.64 ± 0.18%ID/g, respectively). The data of the biodistribution study in the U87-MG xenograft model revealed that these radiotracers could accumulate in the tumor site, and the highest tumor uptake was observed at 60min post-injection (3.38 ± 0.65 and 3.27 ± 0.5%ID/g, respectively). The injection of pimozide can block the tumor's radiotracer uptake, indicating the binding of these radiotracers to the 5-HT7R. The imaging study in the xenograft model also confirms the biodistribution data. The acquired images clearly show the tumor site, and the tumor-to-muscle ratio for 99mTc(CO)3-[6] and 99mTc(CO)3-[7] at 60min was 3.33 and 3.88, respectively. CONCLUSIONS: 99mTc(CO)3-[6] and 99mTc(CO)3-[7] can visualize tumorin theU87-MG xenograft modeldueto their affinitytoward5-HT7R.

Design, synthesis and evaluation of novel pyrido fused piperazine derivatives: In vitro cytotoxicity study over various cancer cell lines

In the present work, a series of novel pyrido bearing a fused piperazine ring derivatives has been synthesized via suzuki and acid–amine coupling reactions. The synthesized compounds were screened for their in vitro cytotoxic activity against nine different cancer cell lines such as U-251, Panc-1, MCF-7, HepG2, DU-145, A549, 786-O, OVCAR3 and HCT-116. Synthesized compound also screened under normal cell lines like human lungs normal cell line (WI38) and Mouse embryonic normal cell line (NIH3T3) to evaluate safety of synthesized compounds. The bioassay results indicates that synthesized compounds (cpd-S10, cpd-12, cpd-19, cpd-32, cpd-33, cpd-36 and cpd-38) to be moderately effective towards various cancer cell lines (DU-145, PanC1, MCF7, U-251, HCT-116, 786-O, HepG2, A549, OVCAR-3) in the in vitro testing.

Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability.

The ongoing transmission of SARS-CoV-2 necessitates the development of additional potent antiviral agents capable of combating the current highly infectious variants and future coronaviruses. Here, we present the discovery of potent nonpeptide main protease (Mpro) inhibitors with prominent antiviral activity and improved pharmacokinetic properties. Three series of 1,2,4-trisubstituted piperazine derivatives were designed and synthesized, and the optimal GC-78-HCl demonstrated high enzyme-inhibitory potency (IC50 = 0.19 μM) and exhibited excellent antiviral activity (EC50 = 0.40 μM), reaching the same level as Nirmatrelvir (EC50 = 0.38 μM). Additionally, GC-78-HCl displayed potent antiviral activities against various SARS-CoV-2 variants as well as HCoV-OC43 and HCoV-229E, indicating its potential broad-spectrum anticoronaviral activity. Notably, the pharmacokinetic properties of GC-78-HCl were somewhat enhanced compared to those of the lead compound. Furthermore, the cocrystal and molecular docking elucidated the mechanism of action. In conclusion, we discovered a novel nonpeptidic Mpro inhibitor with promising antiviral activity and a favorable pharmacokinetic profile.

Chalcogen-Varied Imidazolone Derivatives as Antibiotic Resistance Breakers in Staphylococcus aureus Strains.

In this study, a search for new therapeutic agents that may improve the antibacterial activity of conventional antibiotics and help to successfully overcome methicillin-resistant Staphylococcus aureus (MRSA) infections has been conducted. The purpose of this work was to extend the scope of our preliminary studies and to evaluate the adjuvant potency of new derivatives in a set of S. aureus clinical isolates. The study confirmed the high efficacy of piperazine derivatives of 5-arylideneimidazol-4-one (7-9) tested previously, and it enabled the authors to identify even more efficient modulators of bacterial resistance among new analogs. The greatest capacity to enhance oxacillin activity was determined for 1-benzhydrylpiperazine 5-spirofluorenehydantoin derivative (13) which, at concentrations as low as 0.0625 mM, restores the effectiveness of β-lactam antibiotics against MRSA strains. In silico studies showed that the probable mechanism of action of 13 is related to the binding of the molecule with the allosteric site of PBP2a. Interestingly, thiazole derivatives tested were shown to act as both oxacillin and erythromycin conjugators in S. aureus isolates, suggesting a complex mode of action (i.e., influence on the Msr(A) efflux pump). This high enhancer activity indicates the high potential of imidazolones to become commercially available antibiotic adjuvants.